• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference

    11/8/24 7:50:53 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BCTX alert in real time by email
    • BriaCell's clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer (Bria-PROS+™) generate robust anti-cancer activity in preclinical models
    • Novel therapy activates both innate and adaptive immune systems
    • Proof of concept Phase 1/2 Study of Bria-BRES™ in metastatic breast cancer currently underway

    PHILADELPHIA and VANCOUVER, British Columbia, Nov. 08, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today is pleased to report preclinical data showing strong anti-cancer activity of its next generation, personalized, off-the-shelf, cell-based breast and prostate cancer immunotherapies, Bria-BRES+™ and Bria-PROS+™, respectively, during a poster session at the 2024 Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, held November 6-10, 2024, in Houston, TX.

    Bria-OTS+™ is an Off-The-Shelf (i.e. pre-manufactured and ready for use) cell-based personalized immunotherapy platform for cancer. First generation Bria-OTS™ immunotherapy is HLA matched to individual patients and expresses a variety of cancer-related antigens, including Tumor-Associated Antigens (TAAs) and Post-Translational Modifications (PTMs). Bria-OTS+™ further expresses multiple immune activating cytokines and co-stimulatory molecules in addition to immune boosting granulocyte-macrophage colony-stimulating factor (GM-CSF). The Bria-OTS+™ platform technology includes both Bria-BRES+™ and Bria-PROS+™, expansions of the Bria-OTS™ program.

    "Bria-OTS+™ represents a significant advancement in the fight against cancer, leveraging gene-modified allogeneic tumor cells as a comprehensive immunotherapeutic platform. This innovative approach is set to address major challenges in cancer therapy, including effective antigen selection, T-cell immune escape, and manufacturing complexities. The development of Bria-OTS+™ builds on the success of BriaCell's initial platform, Bria-IMT™, which has shown promising clinical results in metastatic breast cancer," commented Miguel A. Lopez-Lago, PhD, BriaCell's Chief Scientific Officer.

    "We are thrilled with our pre-clinical data confirming the expected high potency and potential for long-lasting anti-tumor activity of our novel next-generation immunotherapy in multiple cancer models," commented Dr. William V. Williams, BriaCell's President and CEO. "We believe that activating both adaptive and innate immune systems is a novel and highly effective approach for cancer treatment and look forward to generating proof of concept data in our ongoing Phase 1/2 study of Bria-OTS™ in metastatic breast cancer, and other cancers."

    The poster is summarized below and linked here: https://briacell.com/scientific-publications/.

    Title: Bria-OTS+™: A Cellular Cancer Vaccine Platform Targeting Innate and Adaptive Immunity

    Location: Exhibit Halls A B George R. Brown Convention Center, Houston, TX

    Date and Time: Friday, Nov. 8, 2024, 9:00 am -7:00 pm CST

    Results:

    • Both Bria-BRES+™ (clinical candidate for breast cancer) and Bria-PROS+™ (clinical candidate for prostate cancer) activated key components of the innate immune system, the body's first line of defense against cancer, including Natural Killer (NK) cells and NKT cells in preclinical cancer models.
    • Activation of the innate immune system by Bria-BRES+™ and Bria-PROS+™ was mediated by CD86, IL-12, NKG2D and inhibited by HLA class I molecules
    • Bria-BRES+™ and Bria-PROS+™ both effectively activated immune cells to destroy breast cancer and prostate cancer cells in a pre-clinical cancer model
    • Both Bria-BRES+™ and Bria-PROS+™ activated key adaptive immune responses demonstrating immunological memory and suggesting potent and durable anti-cancer effects in cancer patients

    Conclusion:

    The characteristics of the next generation Bria-OTS+™ immunotherapy platform include the following:

    • Engages multiple facets of the adaptive immune response
    • Activates components of the innate immune system
    • Specifically activates Natural Killer (NK) cells to offset cancer immune escape caused by the loss of human leukocyte antigens (HLA)
    • Designed for both personalized and ready-to-use therapy with long-term stability
    • Simplified intradermal administration (injection into the skin)
    • Targeted mechanism of action expected drive high efficacy with a favorable side effect profile

    "The preclinical data demonstrating targeted activation of both the innate and adaptive immune systems suggest potential efficacy and safety across multiple cancer indications," stated Adam M. Brufsky, MD, PhD, FACP, Professor of Medicine at the University of Pittsburgh School of Medicine and Medical Director of the Magee-Women's Cancer Program. "Personalized off-the-shelf cancer immunotherapy is an especially exciting treatment modality that would benefit many cancer patients."

    BriaCell is currently conducting its Phase 1/2 Study of Bria-OTS™ (first generation product), also known as Bria-BRES™, in metastatic breast cancer (listed on ClinicalTrials.gov as NCT06471673). This is a bucket trial with other cancer indications expected to be added soon. The next generation (Bria-OTS+™) is expected to enter the clinic in 1H2025 starting with Bria-PROS+™ for prostate cancer.

    Bria-OTS+™ leverages advanced biomanufacturing techniques, ensuring scalability and cost-effectiveness, crucial for rapid global deployment. It is designed to target a range of cancer types and strong intellectual property strategy protects Bria-OTS+™ innovations and strengthens BriaCell's competitive position. Bria-OTS+™ is designed as an open-ended, modular platform, allowing for continuous refinement and the addition of new components. This flexibility enables BriaCell to rapidly adapt to emerging scientific insights and therapeutic needs, ensuring long-term relevance and effectiveness.

    About BriaCell Therapeutics Corp.

    BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.

    Safe Harbor

    This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about Bria-OTS+™ addressing certain challenges in cancer therapy, such as effective antigen selection, T-cell immune escape, and manufacturing complexities; BriaCell generating proof of concept data in the ongoing Phase 1/2 study of Bria-OTS+™ in various cancers, such as metastatic breast cancer; the preclinical data of Bria-OTS+™ demonstrating potential efficacy and safety across multiple cancer indications; BriaCell's personalized off-the-shelf immunotherapy benefiting many cancer patients; BriaCell continuing its clinical study investigations of its novel targeted immunotherapy candidates, including the addition of new cancer indications; and BriaCell's anticipated timeline of clinical studies on Bria-OTS+™ and Bria-PROS+™, are based on BriaCell's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements, such as those are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under "Risks and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

    Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

    Contact Information

    Company Contact:

    William V. Williams, MD

    President & CEO

    1-888-485-6340

    [email protected] 

    Media Relations:

    Jules Abraham

    CORE IR

    [email protected]

    Investor Relations Contact:

    CORE IR

    [email protected]



    Primary Logo

    Get the next $BCTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCTX

    DatePrice TargetRatingAnalyst
    2/14/2022$25.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BCTX
    SEC Filings

    View All

    BriaCell Therapeutics Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BriaCell Therapeutics Corp. (0001610820) (Filer)

    8/25/25 8:18:16 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by BriaCell Therapeutics Corp.

    S-8 - BriaCell Therapeutics Corp. (0001610820) (Filer)

    7/31/25 7:01:41 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by BriaCell Therapeutics Corp.

    SCHEDULE 13G - BriaCell Therapeutics Corp. (0001610820) (Subject)

    7/28/25 11:38:34 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

    4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

    5/20/24 4:00:14 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. initiated coverage on BriaCell Therapeutics with a new price target

    HC Wainwright & Co. initiated coverage of BriaCell Therapeutics with a rating of Buy and set a new price target of $25.00

    2/14/22 6:04:45 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

    4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

    5/20/24 4:00:14 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Bondarenko Jamieson bought $128,240 worth of shares (28,000 units at $4.58), increasing direct ownership by 20% to 169,856 units

    4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

    12/28/22 4:38:08 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Williams William V.

    4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

    12/28/22 3:22:52 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

    Data from BriaCell and the US National Cancer Institute (NCI) support the cancer cell killing potential of BriaCell's Bria-OTS+ platformBria-OTS+, a novel personalized, off-the-shelf, semi-allogeneic cellular immunotherapy may address urgent unmet medical needs for patients with cancer This study was conducted in collaboration with the NCI PHILADELPHIA and VANCOUVER, British Columbia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the publication of the mechanism of action of its next generat

    8/26/25 7:30:19 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

    US$2,054,651 non-dilutive grant from the US National Cancer Institute to complete manufacturing of Bria-Pros+TM clinical supply and support Phase 1/2a trial in metastatic prostate cancerExpands Bria-OTS+ novel personalized off-the-shelf immunotherapy platform to prostate cancer, an urgent unmet medical needPrincipal Investigator: Dr. William Oh, MD, Yale Cancer Center PHILADELPHIA and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the National Cance

    8/25/25 7:30:25 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BriaCell Announces Proposed Effective Date of Share Consolidation

    PHILADELPHIA and VANCOUVER, British Columbia, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that the Company's board of directors has approved the consolidation (the "Consolidation") of the Company's issued and outstanding common shares (the "Common Shares") on the basis of one (1) post-Consolidation Common Share for every ten (10) pre-Consolidation Common Shares. The Consolidation is being implemented to ensure that the Company continues to comply with the listing requirements of The Nasdaq

    8/21/25 12:00:50 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    Leadership Updates

    Live Leadership Updates

    View All

    BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

    PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the "Shareholders") for the year ended July 31, 2024 held on February 5, 2025 (the "Meeting"). A total of 36.26% of the Company's issued and outstanding common shares (the "Common Shares") were voted at the Meeting. At the Meeting, the Shareholders overwhelmingly voted in favour of all proposed resolutions, consisting of

    2/5/25 6:15:47 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025

    PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company's Annual General Meeting of Shareholders (the "Meeting"), which was originally scheduled to be held on Thursday, January 23, 2025, has been rescheduled. The Meeting is now scheduled to be held on Wednesday, February 5, 2025, at 9:00 a.m. (ET) at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. The record date for the Meeting, December 9, 2024, is unchanged and applies to the postponed

    1/3/25 5:05:00 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

    PHILADELPHIA and VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company will be relying on, and has satisfied all of the conditions to rely on, CSA Coordinated Blanket Order 51-931 for exemption from the requirements to send proxy-related materials (the "Meeting Materials") for its upcoming annual general meeting (the "Meeting") to be held on Thursday, January 23, 2025, at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. at 10:00 a.m. (EST) due to the susp

    12/17/24 4:05:59 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    Financials

    Live finance-specific insights

    View All

    ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023

    The Company achieved revenue of $20.7 million during the year ended April 30, 2023, a 6.7% increase from the year ended April 30, 2022. YoY growth increases to 9.0% when adjusting for the effects of currency translation. The Company recorded total revenue of $5.6 million during the three months ended April 30, 2023, the highest quarterly revenue total the Company has recorded. IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for the full fiscal year 2023 ended April 30, 2023. "As we usher in Fiscal Year 2024, we carry with us a strong momentum from the impressive

    7/7/23 8:10:00 AM ET
    $BCTX
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

    SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)

    12/12/24 6:06:07 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

    SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)

    12/10/24 6:06:45 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

    SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)

    12/5/24 7:45:06 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care